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Abstract
Introduction: Interleukin 17A (IL17A) plays a key role in host defense against microbial infection including Gram-
positive bacteria. Genetic factors contribute to the host defense, but the role of IL17A single nucleotide
polymorphisms (SNPs) has not yet been investigated in severe sepsis. Therefore, we hypothesized that SNPs in the
IL17A gene alter susceptibility to infection and clinical outcome of severe sepsis.
Methods: We tested for the association of IL17A SNPs with susceptibility to infection and clinical outcome of
severe sepsis using two cohorts of European ancestry (derivation cohort, St Paul’s Hospital (SPH), n = 679;
validation cohort, Vasopressin and Septic Shock Trial (VASST), n = 517). The primary outcome variable was
susceptibility to Gram-positive bacterial infection. The secondary outcome variable was 28-day mortality.
Results: Of four tested IL17A tag SNPs (rs4711998, rs8193036, rs2275913, rs1974226), rs1974226 SNP was associated
with altered susceptibility to Gram-positive infection in the derivation SPH cohort (corrected P = 0.014). Patients
having the rs1974226 GG genotype were more susceptible to Gram-positive infection, compared to AG/AA
genotype in the two cohorts of severe sepsis (SPH, P = 0.0036, odds ratio (OR) 2.19, 95% confidence interval (CI)
1.28-3.72; VASST, P = 0.011, OR 1.95, 95%CI 1.16-3.27) and in the subgroup having lung infection (P = 0.017, OR
1.90, 95%CI 1.12-3.21). Furthermore, the IL17A rs1974226 G allele was associated with increased 28-day mortality in
two cohorts (SPH, adjusted OR 1.44, 95%CI 1.04-2.02, P = 0.029; VASST, adjusted OR 1.67, 95%CI 1.17-2.40, P =
0.0052).
Conclusions: IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and 28-day
mortality of severe sepsis.
Introduction
Interleukin 17A (IL17A) plays a key role in host defense
against infection and development of inflammatory dis-
eases [1-5]. IL17A production is increased as an innate
response to bacterial infection in human immune cells
[6,7], and elevated serum IL17A levels are observed in
human [8] and animal models of sepsis [9,10]. In con-
trast, deficiency of the IL17 response impairs bacterial
clearance, delays recovery from infection [1,11] and
increases susceptibility to infection [12-15].
Recently two autosomal mutations of IL17 pathway
genes were identified in patients with chronic
mucocutaneous candidiasis disease, which is character-
ized by recurrent or persistent mucocutaneous infec-
tions by Candida albicans and Staphylococcus aureus
[16]. The mutations, single nucleotide substitutions in
the coding region of IL17 genes, abolish the IL17
immune response leading to persistent infections [16].
IL17 deficiency appears to differentially increase sus-
ceptibility to infection including S. aureus [12] and C.
albicans [13-15]. These discoveries highlight the impor-
tance of the IL17A gene on infection and, in particular,
on Gram-positive and fungal infections. Severe sepsis is
a leading cause of death in intensive care units (ICUs)
[17]. Multiple studies have shown that single nucleotide
polymorphisms (SNPs) in important immune response
genes alter susceptibility to infection and/or outcome of
severe sepsis [18-21], but the role of IL17A SNPs has
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any medium, provided the original work is properly cited.not yet been investigated in severe sepsis. Gram-positive
infections, including S. aureus, are very common patho-
gens isolated from severe sepsis patients [22,23], while
fungal infections are somewhat less common. Thus, we
tested the hypothesis that IL17A genetic polymorphisms
alter susceptibility of patients to Gram-positive infection
using isolated pathogens from patients in two large
severe sepsis cohorts of European ancestry. We subse-
quently tested for association of IL17A genotype with
survival from severe sepsis.
Materials and methods
Patients
St Paul’s Hospital (SPH) Cohort
Severe sepsis was defined b yt h ep r e s e n c eo ft w oo r
more diagnostic criteria for the systemic inflammatory
response syndrome [24], proven or suspected infection,
and at least one new organ dysfunction by Brussels cri-
teria [25]. Septic shock was defined by severe sepsis plus
hypotension [25] despite adequate fluid resuscitation.
All patients admitted to the ICU at St Paul’s Hospital
(SPH) in Vancouver, Canada between July 2000 and Jan-
uary 2004 were screened (n = 1, 626). Of these, 691
patients of European ancestry had severe sepsis, were
extensively phenotyped [26], and had DNA available.
Twelve patients, who were also enrolled in the Vaso-
pressin and Septic Shock Trial (VASST) [25] were
excluded from this cohort to avoid duplication. Thus,
679 severe sepsis patients, including 453 septic shock
patients, were analyzed in this study. The Institutional
Review Board at SPH and the University of British
Columbia (UBC) approved the study. For this fully
anonymized analysis the UBC and SPH Review Boards
waived the need for informed patient consent.
Vasopressin and Septic Shock Trial (VASST) Cohort
VASST was a multicenter, randomized, double blind,
and controlled trial evaluating the efficacy of vasopressin
versus norepinephrine in a total of 778 septic shock
patients [25]. Of these, 517 patients of European ances-
try had DNA available and were included in the analysis.
The research ethics boards of all participating institu-
tions approved this trial and written informed consent
was obtained from all patients or their authorized repre-
sentatives. The research ethics board at the coordinating
center (UBC) approved the genetic analysis.
Microbiology
We assessed all microbiological cultures taken at the
time of admission to the ICU for patients in the SPH
cohort. Results from cultures that were collected from 48
hours prior to enrollment to 48 hours after enrollment in
the VASST cohort [25] were analyzed. We defined bac-
terial infection in this study as clinical evidence of infec-
tion associated with positive microbiological culture,
excluding the cultures judged to be positive due to con-
tamination or colonization by the attending physician.
We categorized positive microbial cultures into Gram-
positive bacteria, Gram-negative bacteria or fungus since
these are the three major pathogen categories indentified
in previous studies of sepsis in ICUs [23,27], and
included in the analysis. The source of a positive culture
was categorized as lung (sputum), blood, abdomen (peri-
toneal fluid, abscess drainage, biliary tract), skin (soft tis-
sues or wounds), genitourinary system (urine) or other.
Selection of SNPs and genotyping
Tag SNPs for IL17A gene were identified using a multi-
marker tagging algorithm of Tagger software [28]. To
identify tag SNPs, we used the sequence of the IL17A
gene plus 2, 000 bp of 5’ upstream sequence and consid-
ered all SNPs with a minor-allele frequency (MAF) >
10% in the HapMap Phase 2+3 Utah residents with
Northern and Western European ancestry from the
Centre d’Etude du Polymorphisme Humain (CEPH) col-
lection (CEU) data [29] composed of 174 individuals
and chose an r
2 threshold of 0.5. This identified four tag
SNPs (rs4711998, rs8193036, rs2275913, rs1974226),
which were genotyped in the SPH derivation cohort.
IL17A rs1974226 was genotyped in the VASST replica-
tion cohort. DNA was extracted from the buffy coat of
discarded blood samples using a QIAamp DNA maxi kit
(Qiagen, Mississauga, ON, Canada) and genotyped using
the Illumina Golden Gate assay (Illumina, San Diego,
CA). We performed quality control of the genotyping
using 5% repeat and HapMap Coriell DNA controls. For
5% repeat genotyping and Coriell controls, the concor-
dance rate was > 99%. We did not discard any of the
IL17A SNPs based on the quality control metrics.
Statistical analysis
The primary outcome variable was susceptibility to
Gram-positive infection. To screen the four SNPs of the
IL17A gene in the derivation cohort we used an Armi-
tage’s trend test followed by Bonferroni correction for
multiple comparisons. Power for the genetic association
of susceptibility to infection by Gram-positive bacteria
was calculated using the Genetic Power Calculator [30].
We tested a joint analysis across the SPH and VASST
cohorts on genetic susceptibility to Gram-positive,
Gram-negative infection and Gram-positive infection by
site of infection using a logistic regression controlling for
the cohort. For the secondary analysis, we chose logistic
regression to test for the genetic effect on 28-day mortal-
ity to allow for correction of potential confounding fac-
tors, including age, gender, surgical versus medical
primary diagnosis and septic shock as covariates.
We tested for differences in baseline characteristics by
genotype using a chi-square test for categorical data and
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Hardy-Weinberg equilibrium using a chi-square test
(threshold P-value < 0.05 was considered significant).
We tested for differences in survival curves using a log-
rank test for trend. R2 measure of linkage disequilibrium
was calculated using HapMap Phase 3 genotyping data
(Han Chinese in Beijing (HCB), Japanese in Tokyo
(JPT), CEU) in the genome variation server [31]. Differ-
ences were considered significant using a two-tailed P <
0.05. Analyses were performed using R (version 2.8.1)
[32] and SPSS (SPSS, version 16, Chicago, IL) statistical
software packages.
Results
A total of 679 severe sepsis patients of European ances-
try in the derivation SPH cohort were successfully geno-
typed for four tag SNPs of IL17A.P a t i e n t sw i t ha
positive microbiological culture (n =3 0 1 )h a ds i m i l a r
baseline characteristics to the entire population in the
derivation cohort (Table 1) and had similar allele fre-
quencies to those of HapMap European ancestry data
(Table 2). IL17A is reported to be essential for host
defense against Gram-positive bacterial infection [1].
We first tested for the association of four SNPs with
susceptibility to Gram-positive infection using the Armi-
tage trend test for the additive model in the derivation
cohort (Table 2). Of the four SNPs, the major G allele
of IL17A rs1974226 G/A was significantly associated
with increased susceptibility to infection by Gram-
positive bacteria (percentages of positive culture: AA
38.5%, AG 46.4%, GG 64.2%, uncorrected P = 0.0037,
Bonferroni corrected P = 0.014) (Table 2).
Whether the observation that IL17A rs1974226 geno-
type altered susceptibility to infection, is specific to
Gram-positive bacteria is unknown. Therefore, we next
tested for genetic association of altered susceptibility to
infection by three pathogen categories including Gram-
positive bacteria, Gram-negative bacteria and fungus in
the SPH derivation cohort. Due to the small sample size
of the minor homozygote AA genotype patients who
had a positive culture (SPH AA genotype; Gram-positive
n = 5, Gram-negative n =8 ,f u n g u sn =0 ,m i x e dn =1 ,
total n = 14), we compared AA+AG genotype versus
GG genotype in this analysis. In the derivation SPH
cohort, the GG genotype patients had increased suscept-
ibility to Gram-positive bacterial infection (AA+AG vs.
GG, Gram-positive, P = 0.0036, odds ratio (OR) 2.19,
95% confidence interval (CI) 1.28-3.72) and decreased
susceptibility to Gram-negative bacterial infection (AA
+AG vs. GG, Gram-negative, P = 0.0086, OR 0.49 95%
CI 0.29-0.84) (Figure 1). We subsequently tested for
replication using the validation VASST cohort of Eur-
opean ancestry, which was successfully genotyped for
IL17A rs1974226. VASST patients with a positive micro-
biological culture (n = 282) had a similar allele fre-
quency (MAF = 0.195) compared to HapMap and SPH
(Table 1) and were in Hardy-Weinberg equilibrium (P =
0.63). In accord with the observation in the derivation
Table 1 Characteristics of culture-positive patients in two cohorts of severe sepsis
SPH VASST
Culture Positive All Culture Positive All
(n = 301) (n = 679) (n = 282) (n = 517)
Age-years 58 (45-71) 59 (46-72) 63 (50-73) 63 (51-73)
Gender -% male 65.4 66.0 60.3 60.9
APACHE II 24 (18-30) 23 (18-29) 26 (21-31) 26 (21-32)
Surgical -% 26.6 28.7 19.1 21.3
Septic shock-number (%) 208 (69.1) 453 (66.7) 282 (100) 517 (100)
Pathogens-number (%)
Gram-positive bacteria alone 152 (50.5) 115 (40.8)
Gram-negative bacteria alone 100 (33.2) 82 (29.1)
Fungus alone 9 (3.0) 37 (13.1)
Mixed 40 (13.3) 48 (17.0)
Source of a positive culture-number (%)
Lung 126 (41.9) 140 (49.6)
Blood 115 (38.2) 131 (46.5)
Abdomen 20 (6.6) 53 (18.8)
Skin and soft tissue 21 (7.0) 36 (12.8)
Genitourinary system 16 (5.3) 17 (6.0)
Other 3 (1.0) 29 (10.3)
APACHE, Acute Physiology and Chronic Health Evaluation; SPH, St. Paul’s Hospital; VASST, Vasopressin and Septic Shock Trial
Data are median (interquartile range) for continuous variables.
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susceptibility to Gram-positive bacterial infection com-
pared to those with the AA+AG genotype in the replica-
tion cohort (P = 0.011, OR 1.95, 95%CI 1.16-3.27)
(Figure 1). When we calculated power to detect an asso-
ciation between IL17A rs1974226 genotype (GG versus
AG/AA) and Gram-positive infection, we used the
observed prevalences (Gram-positive bacteria, 0.505
(SPH), 0.408 (VASST)), observed allele frequencies and
a relative risk = 2.0. We found that our study had a
99.8% power for SPH and 98.0% power for VASST
(alpha = 0.05) of detecting a genotype effect. Joint analy-
sis across the SPH and VASST cohorts using a logistic
regression controlling for the cohorts yields the same
conclusion for Gram-positive bacterial infection (AA
+AG versus GG, P =1 . 4×1 0
-4, OR 2.06, 95%CI 1.42-
2.99). A non-significant trend in the same direction of
altered susceptibility to Gram-negative infection was
observed in the VASST cohort (P = 0.13, OR 0.66, 95%
CI 0.39-1.13). In the joint analysis across the SPH and
VASST cohorts, the GG genotype patients had
decreased susceptibility to Gram-negative bacterial
infection (AA+AG versus GG, P = 0.0035, OR 0.57, 95%
CI 0.39-0.83). There was no difference of genetic sus-
ceptibility to fungal infection in the two cohorts (AA/
AG versus. GG, SPH, 4.9% versus 2.8%, P =0 . 3 3 ;
VASST, 15.3% versus 12.0%, P = 0.43), however the
number of patients having a fungal infection was low so
that this negative result has limited statistical power.
We further tested for the altered genetic susceptibility
to Gram-positive bacteria by site of infection (Table 1).
We combined two cohorts due to smaller subset sample
size and analyzed using a logistic regression controlling
for the cohort. The GG genotype patients had signifi-
cantly increased Gram-positive bacterial infections com-
pared to the AA/AG genotype in the lung (P = 0.017, OR
Table 2 Allele frequency and association of interleukin17A polymorphisms with Gram-positive bacterial infection in
the derivation cohort of severe sepsis
Location
a
base pair
Major/minor allele MAF (HapMap
b) HWE
P value
c
Odds Ratio (95% CI) P value
d
(Corrected P value
e)
rs4711998 -832 G/A 0.326 (0.217) 0.025 1.13 (0.80-1.60) 0.48
rs8193036 -692 T/C 0.287 (0.241) 0.53 1.41 (0.97-2.05) 0.073
rs2275913 -399 G/A 0.331 (0.383) 0.79 1.45 (1.01-2.10) 0.045 (0.18)
rs1974226 +4150 (3’ UTR) G/A 0.182 (0.179) 0.10 1.89 (1.22-2.92) 0.0037 (0.015)
HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; UTR, untranslated region.
aRelative distance to transcription start site;
bMinor allele frequency of HapMap Utah residents with Northern and Western European ancestry from the Centre
d’Etude du Polymorphisme Humain collection (CEU) data;
cHardy-Weinberg equilibrium P values for culture positive patients were calculated using the chi-square
test;
dP values were calculated using Armitage’s test and corrected for multiple comparison by a Bonferroni test
e.
Figure 1 Frequency of patients who had Gram-positive or Gram-negative bacterial culture-positive by IL17A rs1974226 genotype in
two cohorts of severe sepsis. IL17A rs1974226 GG genotype patients had an increased culture-positive rate of Gram-positive bacteria
compared to the AA/AG genotype patients and a decreased rate of Gram-negative bacteria in two cohorts (AA/AG versus GG, SPH, Gram-
positive P = 0.0036, Gram-negative P = 0.0086; VASST, Gram-positive P = 0.011, Gram-negative P = 0.13). SPH, St Paul’s Hospital; VASST,
Vasopressin and Septic Shock Trial. P values were calculated using chi-square test. *P < 0.05
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same direction were observed in the other sites (blood,
P = 0.53; abdomen, P = 0.91; skin and soft tissue (SST),
P = 0.22; genitourinary system (GU), P = 0.25) (Figure 2).
We next tested whether the IL17A rs1974226 altered
the 28-day mortality of septic shock in the two cohorts.
Because VASST only included septic shock patients, we
limited our analysis of the SPH cohort to septic shock
in order to examine cohorts of similar overall severity of
illness. There was no baseline difference by the genotype
of rs1974226 in age, gender, Acute Physiology and
Chronic Health Evaluation (APACHE) II, surgical versus
medical, pre-existing conditions, physiological or labora-
tory variables in the SPH cohort (Table 3). In the
VASST cohort, patients who had rs1974226 GG or AG
genotype had a decreased PaO2/FIO2 ratio compared to
AA genotype in parallel with an increased rate of GG or
AG genotype patients of chronic lung disease (Table 3).
The GG genotype patients had increased mortality over
28 days compared to the AG or AA genotype in the two
cohorts of septic shock (Figure 3, SPH, P =0 . 0 2 9 ;
VASST, P = 0.010, log-rank test for trend: Table 4, G
Figure 2 Frequency of Gram-positive bacteria infection by site.
Patients who had the GG genotype of IL17A rs1974226 SNP had
significantly increased Gram-positive infection compared to AA/AG
genotype in the lung, and non-significant trends in the same
direction were observed in other sites (AA/AG versus GG, SPH
+VASST, lung, P = 0.017; blood, P = 0.53; abdomen, P = 0.91; skin
and soft tissue [SST], P = 0.22; genitourinary system [GU], P = 0.25).
SPH, St Paul’s Hospital; VASST, Vasopressin and Septic Shock Trial. P
values were calculated using a logistic regression controlling for the
cohort. *P < 0.05
Table 3 Baseline characteristics in two cohorts of severe sepsis patients by the genotype of IL17A rs1974226
polymorphism
SPH (n = 679) VASST (n = 517)
IL17A rs1974226 G/A AA AG GG AA AG GG
(n = 39) (n = 174) (n = 466) P (n = 19) (n = 162) (n = 336) P
Age-years 60(47-73) 60(47-71) 59(46-72) 0.96 60(47-71) 66(51-74) 63(51-72) 0.57
Gender -% male 76.9 60.3 67.2 0.089 57.9 55.6 63.7 0.21
APACHE II 21(17-28) 23(17-29) 23(18-29) 0.74 25(19-35) 26(21-32) 27(22-31) 0.63
Surgical -% 30.8 32.2 27.3 0.45 21.1 22.8 20.5 0.84
Septic shock-n(%) 26 (5.7) 125 (27.6) 302 (66.7) 0.24 19 (3.7) 162 (31.3) 336 (65.0) NA
Preexisting disease-n(%)
Chronic heart failure 2(5.1) 13(7.5) 25(5.4) 0.59 1(5.3) 13(8.0) 27(8.0) 0.91
Chronic lung disease 5(12.8) 41(23.6) 79(17.0) 0.10 1(5.3) 39(24.1) 55(16.4) 0.037
Chronic liver disease 4(10.3) 16(9.2) 49(10.5) 0.89 1(5.3) 15(9.3) 36(10.7) 0.69
Chronic renal failure 1(2.6) 9(5.2) 15(3.2) 0.47 2(10.5) 16(9.9) 36(10.7) 0.96
Vasopressin-n(%) 3(7.7) 27(15.5) 63(13.5) 0.43 9(47.4) 86(53.1) 168(50.0) 0.77
Corticosteroids
a -n(%) 9(23.1) 68(39.1) 156(33.5) 0.13 11(57.9) 85(52.5) 184(54.8) 0.84
Corticosteroids-day 4(1-20) 6(2-16) 4(2-12) 0.61 10(6-21) 8(5-16) 8(4-14) 0.64
Activated protein C-n(%) 1(2.6) 4(2.3) 22(4.7) 0.34 0(0) 27(16.7) 43(12.8) 0.11
Variables-Day1
Body temperature-C° 37.8(37.1-38.5) 37.9(37.0-38.6) 37.9(36.6-38.6) 0.73 38.8(37.6-39.3) 38.5(37.5-39.1) 38.5(37.6-39.3) 0.85
Heart rate -/min 115(105-120) 106(95-126) 112(95-130) 0.67 126(107-140) 128(115-140) 125(106-137) 0.12
MAP-mmHg 59(52-71) 57(51-65) 58(52-68) 0.34 58(51-63) 56(50-61) 55(50-61) 0.60
WBC-10
3/mm
3 12.9(9.0-17.1) 15.0(9.3-21.7) 13.5(9.3-18.9) 0.075 14.3(4.6-19.6) 13.4(8.3-19.9) 13.9(7.7-21.3) 0.69
Platelet-10
3/mm
3 149(97-183) 191(113-261) 171(95-259) 0.091 150(123-224) 145(74-246) 165(86-263) 0.44
PaO2/FIO2 ratio-mmHg 162(106-234) 154(106-224) 158(98-229) 0.84 233(182-317) 198(153-263) 190(131-251) 0.040
Creatinine -μmol/L 165(73-295) 112(73-240) 126(80-231) 0.50 190(96-297) 149(90-228) 154(90-270) 0.38
APACHE, Acute Physiology and Chronic Health Evaluation; MAP, mean arterial pressure; n, number; NA, not applicable; SPH, St Paul’s Hospital; VASST, Vasopressin
and Septic Shock Trial; WBC, white blood cell count.
aCorticosteroids, low dose corticosteroid.
Data are median (interquartile range) for continuous variables. P values were calculated with the use of chi-square test and Kruskal Wallis test.
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1.04-2.02, P = 0.029; VASST, adjusted OR 1.67, 95% CI
1.17-2.40, P = 0.0052, logistic regression). In addition,
repeating the analysis of the SPH cohort including all
patients in a logistic regression analysis adjusted by
including septic shock as a covariate yielded the same
conclusions (SPH (severe sepsis), adjusted OR 1.35, 95%
CI 1.01-1.80 P = 0.042).
Discussion
We found that patients who had the GG genotype of
IL17A rs1974226 G/A SNP had increased susceptibility
to Gram-positive bacterial infection in the derivation
cohort and this result was replicated in the validation
cohort. In addition, this genotype was significantly asso-
ciated with adverse clinical outcome of severe sepsis.
We found that the G allele of the IL17A SNP was asso-
ciated with increased 28-day mortality in both cohorts
of severe sepsis/septic shock patients.
IL17A is an essential cytokine for host defense against
bacteria [1,9], which is produced by a variety of cells
[2,3] including T cells (T helper 17, gδ T, NKT cell),
lymphoid-tissue inducer-like cells [33], neutrophils [34]
and intestinal Paneth cell [35]. Cells triggered by
microbes secrete IL17A, which is then recognized by an
IL17 receptor [2-4]. Subsequent cellular signaling acti-
vates inflammatory pathways including NF-kB and
MAPK/AP-1, which invoke production of pro-inflamma-
tory cytokines, chemokines and antimicrobial peptides,
which induce inflammation required for host defense
[2-4]. Human IL17A-producing cells increase IL17A
production against bacteria or their toxins [6,7]. Serum
IL17A levels were elevated in bacterial sepsis patients
with acute respiratory distress syndrome (ARDS) [8] and
in animal models of abdominal bacterial infection [9,10].
IL17 deficiency in mice impairs microbial clearance,
delays recovery from infection [1,11] and increases sus-
ceptibility to infection including S. aureus [12] and C.
albicans [13-15]. In accord with the observations in
IL17 deficient mice, low birth weight infants who had
blood stream infections had deceased blood IL17 levels
compared to those without blood stream infections [36].
These results are in accord with our current observa-
tions that severe sepsis patients who had the IL17A
rs1974226 GG genotype had increased susceptibility to
Gram-positive infection.
The human IL17A gene is composed of three exons
(two introns) and located on chromosome 6p12 cover-
ing 4, 252 bases of genomic DNA. The transcript (1,
859 bp) has a relatively long 3’UTR region (1, 345 bp),
where the rs1974226 SNP is located. Since the 3’UTR is
involved in regulation of gene expression, such as
mRNA stability and/or degradation as well as translation
efficiency [37,38], a potential mechanism of the
rs1974226 effect is alteration of gene regulation. Alter-
natively, other SNPs in high linkage disequilibrium with
this SNP may have a biological function. In the Cauca-
sian population the at-risk allele (G) is the major allele
of rs1974226 G/A, potentially marking a haplotype that
includes many rare functional SNPs that increase risk,
or the rarer A allele may actually be protective. Of the
four IL17A SNPs screened in this study, two IL17A
Figure 3 Survival curves over 28 days by IL17A rs1974226
genotype in two cohorts of septic shock. Patients with IL17A
rs1974226 GG genotype had increased mortality in the SPH and
VASST cohort of septic shock compared to the AG or AA genotype
patients (SPH P = 0.029, VASST, P = 0.010). SPH, St Paul’s Hospital;
VASST, Vasopressin and Septic Shock Trial. P values were calculated
using a log-rank test for trend.
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susceptibility to inflammatory diseases, such as pediatric
asthma (rs8193036, risk CC genotype, Taiwan) [39],
ulcerative colitis (rs2275913, risk A allele, Japan) [40]
and rheumatoid arthritis (rs2275913, risk GG allele,
Norway and New Zealand) [41]. These reported SNPs
are not in high linkage disequilibrium with rs1974226
(rs8193036 r
2 = 0.028 (HapMap HCB), rs2275913, r
2 =
0.028 (HapMap JPT), r
2 = 0.135 (HapMap CEU)). Thus,
our finding regarding rs1974226 is not identical to these
previous reports but similarly leads to the conclusion
that genetic variation in the IL17A gene alters outcome
from a variety of inflammatory disorders.
The GG genotype was associated with increased sus-
ceptibility to Gram-positive bacterial infection in two
cohorts of severe sepsis patients, whereas a trend
towards decreased susceptibility to Gram-negative bac-
teria was also observed. Genetic associations of patho-
gen specific susceptibility have been documented in
pattern recognition receptors (PRRs) such as Toll-like
receptors (TLRs) [42]. The potential mechanism of the
different pathogen-specific susceptibility may be differ-
ence of PRRs.
IL17 induces neutrophil recruitment in the airways [43],
which is an important mechanism of host defense for the
lung. In accordance with this, we found that the
rs1974226 GG genotype patients had significantly
increased susceptibility to Gram-positive infection in the
lung. While this association was significant for the lung,
associations were not significant for other sites. This
might be due to the small sample sizes of infections found
in other sites. Other limitations of this study are, first, that
we did not investigate mechanisms of action such as
altered IL17A gene expression or alternative splicing by
the IL17A rs1974226 SNP. Thus, further investigation
regarding the genetic effect on IL17A mRNA structure
and mRNA expression levels and protein levels would
strengthen the results of this study. Second, the GG geno-
type had increased susceptibility to Gram-positive infec-
tion and 28-day mortality, but the causal link is not
proven in this study. Third, this study finding of an asso-
ciation of the IL17A rs174226 GG genotype with increased
susceptibility to a category of Gram-positive bacteria
would be strengthened by testing for an association with a
specific Gram-positive bacterial pathogen, such as S. aur-
eus, in further larger studies.
Decreased susceptibility to Gram-negative bacteria
observed in the GG genotype patients in the derivation
cohort did not replicate; this needs further replication
tests in larger cohorts.
Conclusions
To conclude, the IL17A rs1974226 GG genotype is asso-
ciated with increased numbers of Gram-positive infec-
tions and increased 28-day mortality in severe sepsis
patients.
Key messages
￿ Patients of European ancestry having the IL17A
rs1974226 GG genotype were more susceptible to
Gram-positive infection, compared to those having
the AG/AA genotype in the derivation and valida-
tion cohorts of severe sepsis.
￿ The IL17A rs1974226 GG genotype patients had
significantly increased Gram-positive bacterial infec-
tion compared to the AA/AG genotype in the sub-
group having lung infection.
￿ The IL17A rs1974226 G allele was associated with
increased 28-day mortality in both cohorts of severe
sepsis/septic shock patients.
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